$RADX

Radiopharm Theranostics (RADX) said it will hold an End-of-Phase 2 meeting with the FDA on Oct. 1, 2026 to align on pivotal Phase 3 trial design for RAD101 in suspected recurrent brain metastases after radiotherapy. The company cited Phase 2b results showing 93% MRI concordance and selective tumor uptake. RAD101 has Fast Track status and Siemens will manufacture and distribute it for a planned Phase 3 starting Q4 2026.

Radiopharm Theranostics (NASDAQ: RADX) entered a securities purchase agreement for a registered direct offering of 1,281,646 ADSs (384,493,800 ordinary shares) at $3.16 per ADS, raising about $4.1 million gross. Investors also receive unregistered warrants for up to 1,281,646 ADSs, exercisable after shareholder approval at $3.79 per ADS, expiring July 31, 2029. Closing expected around July 28, 2026.

Radiopharm Theranostics (NASDAQ: RADX) shares fell about 21% after the company announced a $13 million capital raise via concurrent U.S. and Australian offerings. It will issue 1,281,646 ADS at $3.16 in a registered direct offering, raising about $4.1 million gross. It also plans warrants at $3.79 per ADS, expiring July 31, 2029, subject to shareholder approval.

Radiopharm Theranostics (RADX) reported positive clinical updates. In a Phase 2b trial, RAD101 met its primary endpoint, showing 86% accuracy for detecting brain metastases across tumor types, with specificity due in Q4 2026. In a Phase 1 trial, RAD204 showed a RECIST-confirmed durable partial response at 90 mCi, with no dose-limiting toxicities. RADX stock last $4.29.

DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025